Xencor (XNCR) Other Non-Current Liabilities (2013 - 2026)

Xencor's (XNCR) quarterly Other Non-Current Liabilities came in at $152000.0 in Q1 2026, down 98.48% on a QoQ basis from $10.0 million in Q4 2024.

Xencor (XNCR) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends

Xencor (XNCR) has 3 years of Other Non-Current Liabilities data on file, last reported at $152000.0 in Q1 2026.

On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $152000.0 in Q1 2026; TTM through Mar 2026 was $152000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $10.0 million, changed N/A from the prior year.
Other Non-Current Liabilities for Q1 2026 stood at $152000.0, down from $10.0 million in the prior quarter.
Over the last five years, Other Non-Current Liabilities for XNCR reached as high as $10.0 million in Q4 2024 and fell as low as $152000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Xencor	1.47 Bn	1.09 Bn	-

Download Data